XML 31 R14.htm IDEA: XBRL DOCUMENT v3.22.4

Note 6 - Goodwill and Intangible Assets, Net

9 Months Ended

Dec. 31, 2022

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

Note 6. Goodwill and Intangible Assets, Net

Intangible assets, the significant majority of which are finite-lived, consist of the following:

		December 31, 2022												March 31, 2022
		Gross Carrying Amount				Accumulated Amortization				Net Carrying Amount				Gross Carrying Amount				Accumulated Amortization				Net Carrying Amount
Customer relationships		$	237,412			$	(80,627	)		$	156,785			$	244,157			$	(67,469	)		$	176,688
Intellectual property			65,871				(17,732	)			48,139				65,893				(12,620	)			53,273
Other intangibles			24,745				(6,222	)			18,523				25,350				(5,194	)			20,156
Total		$	328,028			$	(104,581	)		$	223,447			$	335,400			$	(85,283	)		$	250,117

Amortization expense for finite-lived intangible assets acquired in a business combination was as follows:

		Three Months Ended December 31,								Nine Months Ended December 31,
		2022				2021				2022				2021
Amortization in cost of revenues		$	1,695			$	1,227			$	5,094			$	1,877
Amortization in general and administrative			5,452				4,695				16,479				11,618
Total		$	7,147			$	5,922			$	21,573			$	13,495

For the following fiscal years ending March 31, amortization expense is estimated as follows:

Remainder of 2023		7,250
2024		28,490
2025		26,911
2026		26,149
2027		25,652

The change in the carrying amount of goodwill was as follows:

		Clinical Genomics				Sterilization and Disinfection Control				Biopharmaceutical Development				Calibration Solutions				Total
March 31, 2022		$	135,914			$	29,750			$	88,265			$	37,237			$	291,166
Effect of foreign currency translation			(244	)			(297	)			(7,871	)			(32	)			(8,444	)
Goodwill related to Belyntic acquisition			-				-				2,973				-				2,973
Measurement period adjustment - Agena acquisition			114				-				-				-				114
December 31, 2022		$	135,784			$	29,453			$	83,367			$	37,205			$	285,809

Goodwill acquired in the Biopharmaceutical Development division resulted from the Belyntic acquisition and is tax deductible.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for goodwill and intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI https://asc.fasb.org/topic&trid=2144416

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration